Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG
- Fátima Reyes†1,
- Yanely Tirado†1,
- Alina Puig1,
- Reinier Borrero1,
- Giselle Reyes1,
- Sonsire Fernández1,
- José Luis Pérez1,
- Ramlah Kadir2,
- Caridad Zayas1,
- Mohd Nor Norazmi2, 3Email author,
- María E Sarmiento1 and
- Armando Acosta1
© Reyes et al; licensee BioMed Central Ltd. 2013
Published: 25 February 2013
The only currently available vaccine against tuberculosis (TB) is Mycobacterium bovis Bacille Calmette-Guerin (BCG), which has inconsistent efficacy to protect against the disease in adults. M. tuberculosis (MTB) cell wall components have been implicated in the pathogenicity of TB and therefore have been a prime target for the identification and characterization of cell wall proteins with potential application in vaccine development. In this regard, proteoliposomes (PLs) derived from mycobacteria containing lipids and cell wall proteins could be potential vaccine candidates against TB. In the present study PLs derived from BCG were prepared. These homogeneous population of spherical microparticles was then immunized into Balb/c mice. Sera of immunized animals showed high IgG response and strong cross-reactivity against different MTB antigens.These results showed that BCG PLs could be potential vaccine candidates against TB.
TB remains a major infectious disease which causes high morbidity and mortality worldwide . BCG, an attenuated strain of Mycobacterium bovis (Mb), is the current vaccine approved for human use against TB. It is most effective in protecting children from the disease; while its efficacy in adults is poor especially against pulmonary TB, proving the prevailing necessity to obtain a more effective vaccine .
The availability of the complete genome sequence of MTB and Mb, as well as access to different programs for epitope prediction and homology search between sequences, allows the identification of conserved proteins among both species with the potential of identifying components for new vaccines . Additionally, many studies support the role of mycobacterial cell wall components in the development of TB pathogenesis .
Since mycobacterial cell wall components have been suggested to be potential targets for the development of new TB vaccine formulations, we attempted to use PLs from BCG to determine the immunogenicity and cross-reactivity of these microparticles against MTB. The presence of proteins in the PLs is expected to enhance the immune response against MTB.
Materials and methods
In silico assays
Proteins with possible localization in the cell wall of MTB were retrieved from the scientific literature. From a total of 306 MTB cell wall proteins a set of five immunodominant and immunogenic proteins (Acr, Ag85B, Mce1A, HbhA and L7/L12) were selected for in silico alignment with the corresponding proteins in Mb using ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
Prediction of B cell epitopes of these proteins was performed by using ABCpred server (http://www.imtech.res.in/raghava/abcpred/). Selected B cell epitopes were synthesized in the Centre for Genetic Engineering and Biotechnology (CIGB), Cuba, and were used in the immunogenicity assay.
Preparation and partial characterization of PLs derived from Mb BCG (BCG PLs)
BCG PLs were prepared according to the methodology described by Rodriguez et al . Molecular size of PLs was determined by size exclusion chromatography using an XK 16/100 column packed with Sephacryl S-1000 (Pharmacia). The morphology of BCG PLs was determined by Transmission Electron Microscopy (TEM) with negative staining.
Immunogenicity and cross-reactivity assays
Eighteen male Balb/c mice (5-6 weeks), supplied by the School of Health Sciences (Universiti Sains Malaysia, Malaysia) were used in the experiments. All procedures were carried out according to the international regulations of laboratory animal experimentation  and approved by the USM Animal Ethics Committee.
Three groups of animals (n=6 per group) were inoculated with either 100 µl PBS (negative control), BCG (106 CFU) or BCG PLs (50 mg + Freund's Incomplete Adjuvant) by the intraperitoneal route. Mice were immunized at days zero and 21 and bled for serum collection at days zero, 14, 28 and 35. Sera samples from each group were stored at -20 °C for subsequent analysis.
Humoral immune response and cross-reactivity against MTB were evaluated by indirect ELISA . Coating antigens comprised BCG whole cells (106 CFU/mL), five B cell epitopes from MTB proteins or MTB antigens such as cell wall fraction (CWF), soluble cell wall proteins (SCWP), lipoarabinomanan (LAM) and purified protein derivative (PPD). These antigens were kindly provided by BEI Resources, ATCC, USA.
Data from the in vitro assays were analyzed for statistical significance using a simple ANOVA test. Duncan's multiple range test and Tukey's Post Hoc Test were used for the determination of pairs with significant differences.
Results and discussion
In silico assays
MTB cell wall proteins have been suggested to contain virulence factors . Since the BCG genome is more than 90% homologous to that of MTB , it is reasonable to assume that BCG PLs can be potential vaccine candidates against TB.
The five MTB cell wall proteins selected in our study are 100% identical to their corresponding proteins in BCG (data not shown). This could explain the partial protection afforded by BCG vaccination in humans .
Preparation and partial characterization of BCG PLs
The molecular size of BCG PLs was estimated by the coefficient of Ve/Vt relation obtained from size exclusion chromatography. This coefficient was 0.45, indicating that the molecular size of PLs was above 100 nm, using as reference the characterization studies of VAMENGOC-BC vaccine and V. cholerae PLs [9, 10]. The morphology of BCG PLs as assessed by TEM showed a homogeneous population of spherical structures (results not shown). The molecular size of BCG PLs was also confirmed by TEM.
In addition, animals immunized with BCG PLs produced significantly (p<0.05) higher IgG levels against B cell epitopes compared to those from animals inoculated with PBS (Fig. 1B).
Proteoliposomes from bacteria contain LPS, proteins and other molecules that are known as pathogen-associated molecular patterns (PAMPs), which possess immune enhancing, and modulator effects . The interaction between cell wall proteins, lipids and detergent molecules leads to the extraction and formation of spherical nanoparticles or proteoliposomes . Our results suggest the presence of the five B cell epitopes from MTB in the BCG PLs (Fig.1B). The epitopes identified in silico belong to proteins, which are involved in the pathogenicity of MTB. Therefore, these antigens could be used to stimulate a protective response against TB.
For example, the Acr protein is a major MTB antigen recognized by the sera of a high proportion of TB patients . Recognition of B cell epitope of Ag85B may have significance for protection as this protein is related to the interaction with fibronectin, a key element of the invasion of tissues by MTB . Moreover, Mce1A protein plays an important role in macrophage invasion , so Mce1A-antibodies could affect the entry of mycobacteria into the cell. HbhA protein is involved in extrapulmonary dissemination of MTB . Immune response against these B cell epitopes could prevent the development of extrapulmonaryTB.
In this paper we selected in silico a group of MTB cell wall proteins which posses 100% identity with its counterparts in Mb BCG. These proteins were positively recognised by sera of mice immunized with BCG PLs obtained by detergent extraction method. This result suggests that BCG PLs contain the highly conserved proteins, which also induce a strong humoral immune response and could generate a cross-protective response to MTB infection.
This work was supported by the LRGS Grant (203.PSK.6722001) provided by the Ministry of Higher Education, Malaysia and Ministry of Science and Technology, Cuba.
This article has been published as part of BMC Immunology Volume 14 Supplement 1, 2013: Proceedings from Delivery Systems and Current strategies to drug design. The full contents of the supplement are available online at http://www.biomedcentral.com/bmcimmunol/supplements/14/S1.
- Acosta A, Norazmi MN, Sarmiento ME: Antibody mediated immunity - a missed opportunity in the fight against tuberculosis?. Malays J Med Sci. 17 (2): 66-67.Google Scholar
- Martín C, Bigi F, Gicquel B: New Vaccines against Tuberculosis. Tuberculosis 2007: From basic science to patient care. 2007, 341-360. FirstGoogle Scholar
- Dietrich J, Weldingh K, Andersen P: Prospects for a novel vaccine against tuberculosis. Vet Microbiol. 2006, 112 (2-4): 163-169. 10.1016/j.vetmic.2005.11.030.View ArticlePubMedGoogle Scholar
- Smith I: Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003, 16 (3): 463-496. 10.1128/CMR.16.3.463-496.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Rodriguez L, Tirado Y, Reyes F, Puig A, Kadir R, Borrero R, Fernandez S, Reyes G, Alvarez N, Garcia MA, et al: Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine. 2011, 29 (37): 6236-6241. 10.1016/j.vaccine.2011.06.077.View ArticlePubMedGoogle Scholar
- Canadian Council On Animal Care: Guide to the care and use of experimental animals. 1984, Ottawa, OntGoogle Scholar
- Garnier T, Eiglmeier K, Camus JC, Medina N, Mansoor H, Pryor M, Duthoy S, Grondin S, Lacroix C, Monsempe C, et al: The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci U S A. 2003, 100 (13): 7877-7882. 10.1073/pnas.1130426100.PubMed CentralView ArticlePubMedGoogle Scholar
- Andersen P, Doherty TM: The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005, 3 (8): 656-662. 10.1038/nrmicro1211.View ArticlePubMedGoogle Scholar
- Perez JL, Acevedo R, Callico A, Fernandez Y, Cedre B, Ano G, Gonzalez L, Falero G, Talavera A, Perez O, et al: A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine. 2009, 27 (2): 205-212. 10.1016/j.vaccine.2008.10.052.View ArticlePubMedGoogle Scholar
- Campa C, Sierra VG, Gutierrez MM, Biset G, García LG, Puentes G, et al: Method of producing Neisseria meningitidis B vaccine, and vaccine produced by method. 1997, US, 597,572Google Scholar
- Yuan Y, Crane DD, Simpson RM, Zhu YQ, Hickey MJ, Sherman DR, Barry CE: The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci U S A. 1998, 95 (16): 9578-9583. 10.1073/pnas.95.16.9578.PubMed CentralView ArticlePubMedGoogle Scholar
- Kremer L, Maughan WN, Wilson RA, Dover LG, Besra GS: The M. tuberculosis antigen 85 complex and mycolyltransferase activity. Lett Appl Microbiol. 2002, 34 (4): 233-237. 10.1046/j.1472-765x.2002.01091.x.View ArticlePubMedGoogle Scholar
- Haile Y, Caugant DA, Bjune G, Wiker HG: Mycobacterium tuberculosis mammalian cell entry operon (mce) homologs in Mycobacterium other than tuberculosis (MOTT). FEMS Immunol Med Microbiol. 2002, 33 (2): 125-132. 10.1111/j.1574-695X.2002.tb00581.x.View ArticlePubMedGoogle Scholar
- Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, Menozzi FD: The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature. 2001, 412 (6843): 190-194. 10.1038/35084083.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.